Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293260 · ClinicalTrials.gov registry record · Phase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
A Phase 3 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT07293260: Recruiting Phase 3 study, sponsored by Amgen.
NCT07293260 is a Phase 3 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 406 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07293260, a Phase 3 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Interventions
- DRUG Placebo
- DRUG Olpasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 3 |
What NCT07293260 shows while recruiting
NCT07293260 is an interventional study that assigns participants to a tested intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07293260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07293260 about?
NCT07293260 is a clinical study titled "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial". The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
What is the current status of trial NCT07293260?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2026-03-23. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07293260?
The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).
Who is sponsoring clinical trial NCT07293260?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07293260's enrollment target sits among peer trials
406 913th of 2000 higher than 1,087 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI